Debt-to-equity of Omega Therapeutics, Inc. from 31 Mar 2022 to 30 Sep 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Omega Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 31 Mar 2022 to 30 Sep 2024.
  • Omega Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2024 was 417%, a 380% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Omega Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2024 417% +330% +380% 30 Sep 2024
Q2 2024 284% +231% +436% 30 Jun 2024
Q1 2024 208% +180% +643% 31 Mar 2024
Q4 2023 129% +103% +403% 31 Dec 2023
Q3 2023 87% +66% +315% 30 Sep 2023
Q2 2023 53% +36% +216% 30 Jun 2023
Q1 2023 28% +5.7% +26% 31 Mar 2023
Q4 2022 26% 31 Dec 2022
Q3 2022 21% 30 Sep 2022
Q2 2022 17% 30 Jun 2022
Q1 2022 22% 31 Mar 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.